Trial Profile

A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegipanermin (Primary)
Indications Alzheimer's disease
Focus Proof of concept; Therapeutic Use
Acronyms MINDFuL
Sponsors INmune Bio

Most Recent Events

09 Jul 2026 Results presented in the INmune Bio media release.
02 Jun 2026 According to an INmune Bio media release, data from this trial will be presented at the Alzheimer's Association International Conference (AAIC) 2026 which will take place July 12-15, 2026 in London, UK.
02 Jun 2026 Results presented at INmune Bio media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com